Last updated August 18, 2026
Key finding
EPO treatment was associated with a significant reduction in errors in the most complex reaction time task (−4.7 (−8.1 to −1.3), p = 0.01).
To study if treatment with erythropoietin (EPO) enhances cognitive function during hypoglycemia in patients with type 1 diabetes and hypoglycemia unawareness.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
To study if treatment with erythropoietin (EPO) enhances cognitive function during hypoglycemia in patients with type 1 diabetes and hypoglycemia unawareness.
To study if treatment with erythropoietin (EPO) enhances cognitive function during hypoglycemia in patients with type 1 diabetes and hypoglycemia unawareness.
Limitations were not clearly described in the extracted text.
Published in
Publication details and source links for this paper.
Erythropoietin Treatment and Cognitive Function During Hypoglycemia in Type 1 Diabetes. 2013.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Erythropoietin and Complex reaction time (sustained attention task), Complex reaction time task errors, Counter-regulatory hormone response to hypoglycemia, and 1 more.
This study contributes evidence to
Primary intervention
Erythropoietin
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
4
Evidence pairs
20
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence topic
Save evidence
Intervention
Save evidence
Core evidence
The primary outcomes reported in this study.
Erythropoietin → Complex reaction time (sustained attention task)
Erythropoietin → Complex reaction time (sustained attention task)
Erythropoietin → Complex reaction time task errors
Erythropoietin → Complex reaction time task errors
Erythropoietin → Counter-regulatory hormone response to hypoglycemia
Erythropoietin → Counter-regulatory hormone response to hypoglycemia
Erythropoietin → Hypoglycemia symptom score
Erythropoietin → Hypoglycemia symptom score
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Generated from the study's connected evidence using Evidence Intelligence™.
DPP-4 Inhibitors appears to improve Cognitive Performance.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Complex reaction time (sustained attention task)
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Complex reaction time task errors
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Erythropoietin for Counter-regulatory hormone response to hypoglycemia.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Counter-regulatory hormone response to hypoglycemia
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Erythropoietin for Hypoglycemia symptom score.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Hypoglycemia symptom score
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
